Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 22,600 shares, a drop of 60.8% from the December 15th total of 57,600 shares. Based on an average daily trading volume, of 175,600 shares, the short-interest ratio is presently 0.1 days. Currently, 0.4% of the shares of the stock are short sold.

Adial Pharmaceuticals Stock Down 1.0 %

NASDAQ:ADIL opened at $1.01 on Tuesday. Adial Pharmaceuticals has a 1 year low of $0.77 and a 1 year high of $4.17. The stock’s 50 day simple moving average is $1.06 and its two-hundred day simple moving average is $1.04.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ADIL shares. Rodman & Renshaw initiated coverage on shares of Adial Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $8.00 target price for the company. RODMAN&RENSHAW upgraded Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.